The Cord Blood Registry (CBR) has announced partnerships with the University of Texas Health Science Center at Houston and Georgia Regents University to establish FDA-regulated clinical trials to test the efficacy of intravenous infusions of umbilical cord blood in children with cerebral palsy.
According to statistics from the Center for Disease Control (CDC), one in every 323 children in the United States has been diagnosed with cerebral palsy or related disorders that affect movements, balance, and posture.
In these proposed clinical trials, a child who has been diagnosed with cerebral palsy-type disorders will receive intravenous infusions of their own umbilical cord blood that was banked at the time of their birth.
Because cerebral palsy results from abnormal brain development or brain damage to the motor centers of the developing brain, umbilical cord blood treatments might provide the means to help the brain heal itself. These umbilical cord blood treatments will take place along side more traditional treatments such as surgery, medications, orthopedic braces, and physical, occupational, and speech therapies.